Esperies

Esperion to Participate in Upcoming June Investor Conferences

Retrieved on: 
목요일, 5월 23, 2024
Conference, Patient, Esperies, ESPR, ANN, Health, Risk

ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website .

Key Points: 
  • ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website .
  • Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m.
  • Live webcasts can be accessed on the investor and media section of the Esperion website .
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Retrieved on: 
월요일, 5월 20, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, Bristol Myers Squibb, Patient, Neuroscience, Abivax, Ferris State University, Depression, Esperies, Therapy, Sale, Insys Therapeutics, Idiopathic pulmonary fibrosis, Audit committee, IPO, Esperion Therapeutics, DSM-IV codes, Juventas, Inflammation, Eli Lilly, AstraZeneca, Pharmaceutical industry

Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum’s board.

Key Points: 
  • Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum’s board.
  • “I am extremely pleased to welcome Troy to the Contineum board.
  • Currently, Mr. Ignelzi serves as the Chief Financial Officer at Rapport Therapeutics, Inc., a precision neuromedicines company, where he has served since November 2023.
  • “I am excited to bring my experience with neuroscience companies to the Contineum board and help guide the company’s financial strategy and growth.”

EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates

Retrieved on: 
금요일, 5월 3, 2024
USD, Annual, Alnylam Pharmaceuticals, TTR, Federal Reserve, Agios, BB Biotech, Mitapivat, NAV, Esperies, Accounting, Federal, Cardiomyopathy, NBI, Public expenditure, Prostate cancer, Obesity, Environment, DSM-IV codes, ADC, CRISPR, Patient, Thalassemia, Biotechnology, CRISPR Therapeutics, Initial public offering, Beam Therapeutics, Inflation, CHF, IRA, Drug development, Clinical trial, Significance, Therapy, Pharmaceutical industry

BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates

Key Points: 
  • BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
    The issuer is solely responsible for the content of this announcement.
  • Media release as at April 26, 2024
    Portfolio of BB Biotech AG as at March 31, 2024
    BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
    Investor sentiment in the biotech space continues to be shaped by the general interest rate environment.
  • Net profit for the first quarter of 2024 amounted to CHF 260 mn (net loss of CHF 254 mn in prior-year quarter).
  • While activity in the secondary market has already picked up, there have been few biotech IPOs so far this year.

Esperion to Report First Quarter 2024 Financial Results on May 7

Retrieved on: 
화요일, 4월 23, 2024
ANN, Health, Esperies, ESPR, PIN, Patient, Risk

ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Key Points: 
  • ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.
  • ET to discuss these financial results and provide business updates.
  • Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
  • A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events .

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Retrieved on: 
월요일, 4월 1, 2024
Health, ANN, Risk, Patient, Esperies, ESPR, FDA, Food, Pharmaceutical industry

ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m.

Key Points: 
  • ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m.
  • ET today, April 1, 2024, to commemorate the U.S. Food and Drug Administration’s (FDA) recent approval of broad new labels for Esperion’s products.
  • “We are honored to ring the Nasdaq opening bell to celebrate a significant milestone for Esperion,” said Mr. Koenig.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors

Retrieved on: 
수요일, 3월 27, 2024
Constellation, Single-cell analysis, Lung cancer, EGFR, Health, Biotechnology, Rachel Haurwitz, New Jersey Medical School, Foundation Medicine, Cornell University, University, Knowledge, American Cancer Society, Research, Esperion Therapeutics, Cancer, A.I, Medicine, Summit Health, Esperies, Therapy, Drug development, Partner, MorphoSys, JPMorgan Chase, Thomas Jefferson University Hospital

to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.

Key Points: 
  • to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.
  • Our proprietary discovery engine has identified its first promising targets, and we are preparing to start drug development activities in 2025.
  • Bolstering our Board with such seasoned leaders will be a key factor to success.”
    Dr. Scott Braunstein brings over 30 years of knowledge and experience gained in the biotechnology, pharmaceutical, and biotech portfolio management industries.
  • Dr. Braunstein is currently on the board at Trevena and Caribou Biosciences.

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
화요일, 3월 26, 2024
Risk, Health, Patient, ANN, Conference, Esperies, ESPR, Broadcasting

ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference.

Key Points: 
  • ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference.
  • Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024, at 12:45 PM ET.
  • The Esperion management team will also host investor meetings that same day.
  • A live audio webcast can be accessed on the investor and media section of the Esperion website .

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

Retrieved on: 
월요일, 3월 25, 2024
Health, Tablet, CVD, Bempedoic acid, Risk, Patient, CLEAR, Esperies, Ezetimibe, Safety, ATP, Pharmaceutical industry

At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

Key Points: 
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there.
  • Because when it comes to high cholesterol, getting to goal is not optional.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
금요일, 3월 22, 2024
Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Committee, Spasm, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Esperies, Rupture, FDA, Molina Healthcare, Hypersensitivity, Health, Conference, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Uric acid, Pharmaceutical industry

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • NEXLETOL and NEXLIZET are also the first oral non-statin LDL-C lowering drugs to be approved by the FDA to reduce the risk of CV events in both primary and secondary prevention patients.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor

Retrieved on: 
화요일, 3월 12, 2024
Professional Services, Health, Other Science, Finance, Research, Science, Biotechnology, RAPS, Eli Lilly, AstraZeneca, Ferris State University, Patient, Esperion Therapeutics, Sale, IPO, Pleasure, Esperies, Insys Therapeutics, Therapy, Investment, Multimedia, Pharmaceutical industry

Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.

Key Points: 
  • Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240312683597/en/
    Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors.
  • Over the course of his career, Mr. Ignelzi has raised an impressive $4 billion-plus in capital for life science companies.
  • We are extremely pleased to have him join us,” said Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments.